These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26613544)

  • 1. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
    Jonsson EN; Xie R; Marshall SF; Arends RH
    Br J Clin Pharmacol; 2016 Apr; 81(4):688-99. PubMed ID: 26613544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
    Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
    Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome.
    Nickel JC; Atkinson G; Krieger JN; Mills IW; Pontari M; Shoskes DA; Crook TJ
    Urology; 2012 Nov; 80(5):1105-10. PubMed ID: 23010344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
    Sharma S; Mittapalli RK; Holen KD; Xiong H
    Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
    Kloft C; Graefe EU; Tanswell P; Scott AM; Hofheinz R; Amelsberg A; Karlsson MO
    Invest New Drugs; 2004 Jan; 22(1):39-52. PubMed ID: 14707493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
    Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
    Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.